Zydus Cadila rises on receiving final approval from USFDA to market antidepressant drug

Zydus Cadila rises on receiving final approval from USFDA to market antidepressant drug   

The global pharmaceutical company, Zydus Cadila announced on Thursday that it has received final approval from USFDA for a drug to treat mood disorders. Reacting to the news, its stock gained over a per cent on BSE.  

The company received approval to market Nortriptyline Hydrochloride capsules USP, in the strengths 10 mg, 25 mg, 50 mg & 75 mg. The medicine is used in the treatment of mental or mood problems such as depression. The drug may help improve mood and feelings of well-being, relieve anxiety and tension as well as increase energy level. 

The drug will be manufactured at the company’s manufacturing facility at SEZ, Ahmedabad. 

So far, the company has filed over 400 ANDAs since the commencement of its filing process and currently has 313 approvals. 

Cadila Healthcare is one of the leading innovations driven pharmaceutical companies with a presence across the pharmaceutical value chain of innovating, manufacturing, marketing & selling of finished dosage human formulations, active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products.  

The company commands a 94 per cent market share in artificial sweetener, 34 per cent in face wash, and 4.5 per cent in cardiovascular segment. 

At the time of market closing, the company’s stock was trading at Rs 437.50, up by 0.83 per cent against its previous close of Rs 433.90 on BSE.